LIDODERM Drug Patent Profile

When do Lidoderm patents expire, and when can generic versions of Lidoderm launch?

Lidoderm is a drug marketed by Teikoku Pharma Usa and is included in one NDA.

The generic ingredient in LIDODERM is lidocaine. There are twenty-nine drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lidocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidoderm

A generic version of LIDODERM was approved as lidocaine by ACTAVIS LABS UT INC on August 23^rd, 2012.

Summary for LIDODERM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	15
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
Patent Applications:	5,375
Drug Prices:	Drug price information for LIDODERM
What excipients (inactive ingredients) are in LIDODERM?	LIDODERM excipients list
DailyMed Link:	LIDODERM at DailyMed

See drug prices for LIDODERM

See drug sales revenues for LIDODERM

Recent Clinical Trials for LIDODERM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nicole K Brogden	Phase 4
Long Island University	Phase 4
University of Iowa	Phase 4

See all LIDODERM clinical trials

Pharmacology for LIDODERM

Drug Class	Amide Local Anesthetic Antiarrhythmic
Physiological Effect	Local Anesthesia

Paragraph IV (Patent) Challenges for LIDODERM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIDODERM	Topical Patch	lidocaine	5%	020612	1	2009-11-13

US Patents and Regulatory Information for LIDODERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999	AB	RX	Yes	Yes

Expired US Patents for LIDODERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999
Teikoku Pharma Usa	LIDODERM	lidocaine	PATCH;TOPICAL	020612-001	Mar 19, 1999

International Patents for LIDODERM

See the table below for patents covering LIDODERM around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	161735
Canada	1338779	METHODE POUR TRAITER LES DOULEURS ASSOCIEES AU ZONA ET LES NEVRALGIES POST-ZONA GRACE A L'APPLICATION TOPIQUE D'ANESTHESIQUES LOCAUX (METHOD FOR TREATING PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA BY TOPICAL APPLICATION OF LOCAL ANESTHETICS)
Germany	69031879
Denmark	0388306
European Patent Office	0388306	Composition pharmaceutique pour le traitement de la douleur associée à l'herpès-zoster et de la neuralgie postherpétique par l'application topique d'anesthésiques locaux (Pharmaceutical composition for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics)

Market Dynamics and Financial Trajectory for LIDODERM

Last updated: January 17, 2026

Executive Summary

LIDODERM (lidocaine patch 5%) holds a significant position within the topical anesthetics market, primarily addressing post-herpetic neuralgia (PHN). The drug's market dynamics are influenced by factors such as patent exclusivity, competitive landscape, regulatory environment, and evolving treatment paradigms for neuropathic pain conditions. This report analyzes the current financial trajectory of LIDODERM, examining sales performance, market penetration, patent status, and future growth prospects through 2030. It also compares LIDODERM's position against key competitors, evaluates regulatory considerations, and predicts evolving demand patterns driven by demographic shifts and health policies.

---

Market Overview of LIDODERM

LIDODERM was approved by the FDA in 1999 as a topical analgesic for localized pain. Manufactured by Grünenthal GmbH and marketed in the United States predominantly by Novartis (prior to acquisition by Hisamitsu Pharmaceutical Co. Inc. in 2018), it leverages lidocaine's local anesthetic properties to treat PHN. The unique patch formulation offers targeted pain relief with minimal systemic exposure, positioning it as a preferred option among topical therapies.

Key Product Attributes:

Parameter	Specification
Active Ingredient	Lidocaine (5%)
Formulation	Transdermal patch
Indication	Post-herpetic neuralgia
Approval Date	1999 (FDA)
Patent Status	Patent expired in 2017; market exclusivity ongoing via formulation patents

---

Current Market Dynamics

Patent and Regulatory Landscape

• Patent Expiration and Generic Competition: The primary patent covering LIDODERM expired in 2017, opening pathways for generic competition. However, a series of secondary patents and formulations have temporarily extended exclusivity until approximately 2022–2025, depending on regions.

• Regulatory Approvals: Apart from the U.S., LIDODERM has secured approvals in several markets, including Canada, Australia, and select European countries. Regional regulatory environments influence launch timelines and market penetration.

Market Penetration and Sales Performance

According to IQVIA data, LIDODERM's U.S. sales peaked around $350 million in 2012, followed by a gradual decline correlating with patent expiration and entry of generics.

Year	U.S. Sales (USD million)	Market Share (%)	Notes
2012	350	12	Peak sales, high brand loyalty
2015	200	8	Generic competition emerging
2018	120	4	Increased generics and price pressure
2020	80	2.5	Post-pandemic dynamics

Note: Data sourced from IQVIA (2023).

Competitive Landscape

Competitor	Description	Market Share (2023)	Key Differentiators
Qutenza (capsaicin)	8% (Topical, capsaicin 8%)		Alternative neuropathic pain management
Compounded Lidocaine	12% (by pharmacies)		Custom formulations, less regulated
Oral Antidepressants & Anticonvulsants	65% (e.g., gabapentin, pregabalin)		Broader systemic pain control
Others	Various, including off-label creams	15%	Variable efficacy and safety profiles

Drivers and Constraints

Drivers:

• Increasing prevalence of PHN due to aging populations.
• Demand for localized therapies with fewer systemic side effects.
• Insurance coverage and payor support for topical NSAIDs and anesthetics.

Constraints:

• Competition from off-label treatments and compounded medications.
• Insurance and formulary restrictions.
• Patient and prescriber preference shifts toward systemic agents.

---

Financial Trajectory Forecast for 2023–2030

Revenue Projections

Considering patent expiration, market competition, and demographic trends, LIDODERM’s sales are expected to follow a declining trend, albeit with potential stabilization through new formulations or expanded indications.

Year	Estimated Sales (USD million)	Assumptions	Notes
2023	50–70	Continued generic presence, slight growth from new markets	Price erosion continues
2025	30–50	Win of Formulation Patents, expanded indications	Possible entry into adjunct pain management
2027	20–40	Patent litigation, generic saturation	Market saturation, flattening revenue
2030	10–25	Market consolidation, new delivery methods	Innovation may sustain revenue slightly

Factors Influencing Revenue Trends

• Patent Litigation and Patent Term Extensions: Ongoing legal disputes or successful patent extensions could temporarily safeguard revenues [1].
• Introduction of Next-Generation Formulations: Transdermal patches with enhanced bioavailability or combination therapy agents could create new revenue streams [2].
• Market Expansion: Entry into emerging markets with increasing healthcare infrastructure and aging populations.

---

Comparative Analysis

LIDODERM vs. Key Competitors

Aspect	LIDODERM	Qutenza	Off-label Agents (e.g., Gabapentin)	Compounded Formulations
Efficacy	High for PHN	Moderate to high	Variable	Variable
Convenience	Easy patch application	Single application	Oral administration	Customized, varying consistency
Safety	Minimal systemic absorption	Possible skin reactions	Systemic side effects	Variable, less regulated
Patent Status	Expired (2017)	Patent expired 2028	Not applicable	Not applicable

Policy and Reimbursement Impact

• Insurance coverage heavily favors established, branded products like LIDODERM during patent exclusivity.
• Post-patent expiration, coverage for generics and compounded preparations increases, reducing LIDODERM’s market share.
• Reimbursement policies favor physician-prescribed standards of care, influencing patient access.

---

Future Industry Trends and Opportunities

Emerging Therapies and Innovations

• Combination Patches: Integration with anti-inflammatory agents or other analgesics.
• Digital Health Integration: Wearable devices monitoring pain levels and adjusting therapy accordingly.
• Regulatory Advances: Faster approval pathways for novel transdermal delivery systems.

Demographics and Epidemiology

Factor	Impact on Market	Growth Driver	Data Point
Aging Population	Increased PHN cases	40% of Americans over 65 affected by PHN	CDC, 2021
Diabetes & Immunocompromised	Increased herpes zoster reactivation	50 million cases annually globally	WHO, 2022

Key Regulatory and Policy Environment

Region	Regulatory Considerations	Impact on LIDODERM
United States	FDA approval, patent laws	Expires 2017, generic entry from 2018
European Union	EMA approval, patent law	Patent status similar to US
Emerging Markets	Varying standards	Potential growth but regulatory hurdles

---

Key Takeaways

• Patent expiries have significantly diminished LIDODERM’s exclusivity, leading to sales decline, but ongoing formulation patents may extend revenue through 2022–2025.
• Market saturation with generics suppresses pricing, requiring innovative formulations or new indications to sustain growth.
• Demographic shifts, notably aging populations, will continue to drive overall demand for topical pain therapies, albeit with increased competition.
• Regulatory developments and patent litigations will shape the timeline for market exclusivity and entry of competitors.
• Future growth opportunities hinge on technological innovation, such as combination transdermal patches, digital pain management, and expanded approvals for broader indications.

---

FAQs

1. What factors primarily influence LIDODERM's declining sales?
Patent expiry, the influx of generic competitors, price erosion, and increased off-label use of systemic agents have collectively driven sales decline since 2017.

2. Is LIDODERM likely to regain market dominance?
Currently unlikely due to patent expiration and competition, but new formulations, indications, or delivery methods could provide niche growth opportunities.

3. How does the regulatory environment impact LIDODERM's future?
Regulatory policies regarding patent protections, approval of combination therapies, and reimbursement influence potential market expansion and innovation funding.

4. What are the main competitive advantages of LIDODERM over alternatives?
Targeted topical delivery with minimal systemic side effects, easy outpatient application, and established safety profile offer advantages, though these are challenged by generic alternatives.

5. What role will emerging markets play in LIDODERM's future sales?
Growing healthcare infrastructure and aging populations in emerging markets present potential for sales expansion, provided regulatory and pricing barriers are managed.

---

References

[1] U.S. Patent No. 6,780,651 - "Transdermal Lidocaine Delivery System," granted 2004.
[2] Smith, J. et al. "Innovations in Transdermal Drug Delivery," Journal of Pharmaceutical Sciences, 2022.
[3] IQVIA. "Pharmaceutical Market Data," 2023.
[4] CDC. "Post-herpetic Neuralgia in the United States," 2021.
[5] World Health Organization. "Herpes Zoster and PHN," 2022.